← Every firm
Carolina Infusion, LLC FDA Recalls
16 recalls on file across drugs, 0 of them Class I and 16 still open. This firm is not matched to a listed company.
Newest first
Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.
| Product |
|---|
| QUAD-MIX( PAPAV/PHENTO/ALPROS/TROP) INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosaClass IISep 10, 2026Lack of Assurance of Sterility: Related to processing equi |
| TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on doClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/20, injectable, Packaged in single-use dosage syringes, total mL dispensed based on Class IISep 10, 2026Lack of Assurance of Sterility: Related to processing equip |
| Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/10, injectable, Packaged in single-use dosage syringes, total mL dispensed based on Class IISep 10, 2026Lack of Assurance of Sterility: Related to processing equipm |
| Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/60, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dClass IISep 10, 2026Lack of Assurance of Sterility: Related to processing equipm |
| Tri-MIX (PAPAV/PHENTO/ALPROS),30/2/40, Packaged in single-use dosage syringes, total mL dispensed based on dosage per spClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| Tri-MIX (PAPAV/PHENTO/ALPROS), 30/1/40, injectable, Packaged in single-use dosage syringes, total mL dispensed based on Class IISep 10, 2026Lack of Assurance of Sterility: Related to processing equip |
| Tri-MIX (PAPAV/PHENTO/ALPROS),30/2/20, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on doClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on doClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on doClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specificClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936Class IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| SERMORELIN ACETATE 1 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per spClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |
| SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on doClass IISep 10, 2026Lack of Assurance of Sterility: Related to formulation using |